Abstract：Objective To investigate the protein expression of osteosarcoma stem cell surface biomarkers, CD117 and Stro-1, and their relationship with the clinicopathologic characteristics as well as disease-free survival (DFS).Methods A retrospective study was adopted. Fifty-eight patients with osteosarcoma who were surgically removed and confirmed by pathological examination in Shanghai Jiao Tong University Affiliated Sixth People's Hospital from August 2014 to November 2017 were selected as the observation group, and 13 cases of adjacent bone tissue were used as the control group. Among them, 36 were male and 22 were female. Age 10-67 (23.16 ± 13.47) years. All tissue were collected to construct tissue microarrays. Immunohistochemistry was used to detect the expression of osteosarcoma stem cell biomarkers CD117 and Stro-1 in the observation group and control group. The correlation between CD117 and Stro-1 protein expression in osteosarcoma tissues was observed. The relationship between the expression of CD117, Stro-1 as well as the double positive expression of CD117/Stro-1 protein and the clinicopathological factors and DFS of patients with osteosarcoma was assessed.Result In observation group, the positive expression rates of CD117 and Stro-1 were 51.72% (30/58) and 48.28% (28/58) respectively. In control group, the positive expression rates were both 6/13, of which the differences showed no significance (all P values＞0.05). In observation group,the positive expression of CD117 protein was positively correlated with that of Stro-1 protein (rn=0.864, P＜0.01). The differences in the expression of CD117, Stro-1 and the dual positive expression of CD117/Stro-1 were significant in Enneking surgical staging (χ2=6.501, 7.374, 6.130, all P values＜0.05), but not in the age and gender of patients (all P values＞0.05). Median DFS of 30 patients with positive expression of CD117 was 360.00 days, which was less than that of 30 patients with negative expression,1 260.00 days. Median DFS of 28 patients with positive expression of Stro-1 was 330.00 days, which was less than that of 30 patients with negative expression, 900.00 days. Median DFS of 27 patients with dual positive CD117 and Stro-1 protein was 360.00 days, which was less than that of 31 patients without dual positive expression, 900.00 days. The differences were statistically significant (χ2 = 5.770, 4.638, 5.391, all P values＜0.05).Conclusions The positive expressions of osteosarcoma stem cell biomarkers CD117 and Stro-1 in osteosarcoma tissues are positively correlated. No matter which protein is positive, patients have higher clinical stage and the shorter tumor-free survival time. CD117 and Stro-1are expected to be an important index to predict the postoperative prognosis of patients with osteosarcoma.
Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma-connecting aetiology, biology and therapy[J]. Nat Rev Endocrinol, 2017, 13(8): 480-491. DOI:10.1038/nrendo.2017.16.
[2]
Xu H, Zhu X, Bao H, et al. Genetic and clonal dissection of osteosarcoma progression and lung metastasis[J]. Int J Cancer, 2018, 143(5): 1134-1142. DOI:10.1002/ijc.31389.
[3]
Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance[J]. Cancer Res, 2010, 70(11): 4602-4612. DOI: 10.1158/0008-5472.CAN-09-3463.
[4]
Yu L, Fan Z, Fang S, et al. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling[J]. Oncotarget, 2016, 7(22): 33055-33068. DOI:10.18632/oncotarget.8849.
[5]
付实, 张琍. 组织芯片技术在消化道肿瘤研究中的应用[J]. 中南医学科学杂志, 2017, 45(2): 183-185. DOI:10.15972/j.cnki.43-1509/r.2017.02.019. Fu S, Zhang L, The application of tissue microarray in the research on gastrointestinal tumors[J]. Medical Science Journal of Central South China, 2017, 45(2): 183-185. DOI:10.15972/j.cnki.43-1509/r.2017.02.019.
[6]
周震涛. c-Kit-Gαi/Gab1信号复合物在骨肉瘤细胞增殖与存活中的分子机制的研究[D]. 苏州: 苏州大学, 2017. Zhou ZT. The molecular mechanism of c-kit-Gαi/Gab 1 signal complex in the proliferation and survival of osteosarcoma cells[D]. Suzhou University, 2017.
[7]
Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study[J]. Am J Surg Pathol, 2002, 26(4): 486-492. DOI:10.1097/00000478-200204000-00011.
[8]
林金銮, 林建华, 吴朝阳, 等. 骨肉瘤CD133 CD117 Ki-67的表达及与临床病理因素和危险度的相关性研究[J]. 中国肿瘤临床, 2014, 41(5): 305-310. DOI:10.3969/j.issn.1000-8179.20131802.Lin JL, Lin JH, Wu CY, et al. Expression of CD133, CD117, and Ki-67 in human osteosarcoma and their clinical significance[J]. Chin J Clin Oncol, 2014, 41(05): 305-310. DOI:10.3969/j.issn.1000-8179.20131802.
[9]
Entz-Werlé N, Marcellin L, Gaub MP, et al. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas[J]. J Clin Oncol, 2005, 23(10): 2248-2255. DOI:10.1200/JCO.2005.03.119.
[10]
韩志, 申晟, 秦晓飞, 等. CD117在骨肉瘤组织中的表达及临床意义[J]. 新乡医学院学报, 2018, 35(11): 988-990. DOI:10.7683/xxyxyxb.2018.11.010. Han Z, Shen S, Qin XF, et al. Clinical significance of the expression of CD117 in osteosarcoma tissues[J]. Journal of Xinxiang Medical University, 2018, 35(11): 988-990. DOI:10.7683 /xxyxyxb.2018.11.010.
[11]
Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1[J]. Blood, 1991, 78(1): 55-62.
[12]
Ning H, Lin G, Lue TF, et al. Mesenchymal stem cell marker Stro-1 is a 75 kd endothelial antigen[J]. Biochem Biophys Res Commun, 2011, 413(2): 353-357. DOI:10.1016/j.bbrc.2011.08.104.
[13]
Mas A, Nair S, Laknaur A, et al. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers[J]. Fertil Steril, 2015, 104(1): 225-234.e3. DOI:10.1016/j.fertnstert.2015.04.021.
[14]
Mas A, Prusinski L, Yang Q, et al. Role of Stro1+/CD44+ stem cells in myometrial physiology and uterine remodeling during pregnancy[J]. Biol Reprod, 2017, 96(1): 70-80. DOI:10.1095/biolreprod.116.143461.
[15]
Mas A, Stone L, O'Connor PM, et al. Developmental exposure to endocrine disruptors expands murine myometrial stem cell compartment as a prerequisite to leiomyoma tumorigenesis[J]. Stem Cells, 2017, 35(3): 666-678. DOI:10.1002/stem.2519.
[16]
Shao XJ, Xiang SF, Chen YQ, et al. Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells[J]. Acta Pharmacol Sin, 2019, 40(10): 1343-1350. DOI:10.1038/s41401-019-0262-4.
[17]
Pisciotta A, Carnevale G, Meloni S, et al. Human dental pulp stem cells (hDPSCs): isolation, enrichment and comparative differentiation of two sub-populations[J]. BMC Dev Biol, 2015, 15: 14. DOI:10.1186/s12861-015-0065-x.
[18]
Conserva E, Pisciotta A, Bertoni L, et al. Evaluation of biological response of STRO-1/c-kit enriched human dental pulp stem cells to titanium surfaces treated with two different cleaning systems[J]. Int J Mol Sci, 2019, 20(8): E1868. DOI:10.3390/ijms20081868.
[19]
洪峰,袁高乐,张辉洁,等. 微管不稳定蛋白和cd133在骨肉瘤组织的表达及其临床意义[J]. 中华实验外科杂志, 2017, 34(3): 516-518. DOI:10.3760/cma.j.issn.1001-9030.2017.03.050.Hong F, Yuan GL, Zhang HJ, et al. Expression and clinical implications of stathmin and CD133 in osteosarcoma[J]. Chin J Exp Surg, 2017, 34(3): 516. DOI:10.3760/cma.j.issn.1001-9030.2017.03.050.
2020, Vol. 25 
